NextCell Pharma (NXTCL) Q4 2024 earnings summary

Executive summary

• Focused on developing cell therapies for autoimmune and inflammatory diseases, with ProTrans showing significant effect in type 1 diabetes.

• Cellaviva, the stem cell banking subsidiary, remains the largest in Scandinavia and is expected to grow.

• Clinical milestones achieved, including positive long-term data for ProTrans and rapid recruitment in pediatric studies.

• Rights issue in June 2024 was oversubscribed, raising approximately SEK 40.1 million before costs.

• Growth prioritized over profit, with Cellaviva targeted to become self-sustaining.

Financial highlights

• Operating income for FY 2023/2024 was SEK 11.3 million, down from SEK 14.0 million year-over-year.

• Operating result for the year was SEK -42.0 million, compared to SEK -39.8 million last year.

• Earnings per share improved to SEK -1.03 from SEK -1.16 year-over-year.

• Cash and cash equivalents at year-end were SEK 46.8 million, down from SEK 50.2 million.

• No dividend proposed for the financial year.

Outlook and guidance

• Continued focus on clinical trials, especially ProTrans-Young, with key results expected by May 2025.

• QVance launch expected to generate revenue in 2025 with limited initial investment.

• Cellaviva anticipated to achieve self-sustaining growth in the near term.